

Stephen Forman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3737827/stephen-forman-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

714
papers

12,181
citations

54
h-index

102
g-index

801
ext. papers

14,898
ext. citations

4.4
avg. IF

5.99
L-index

#	Paper	IF	Citations
714	Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. <i>Blood</i> , 2000 , 96, 4075-4083	2.2	1304
713	Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. <i>New England Journal of Medicine</i> , 2016 , 375, 2561-9	59.2	897
712	A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. <i>Blood</i> , 2011 , 118, 1255-63	2.2	382
711	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. <i>Cancer Research</i> , 2006 , 66, 10995-1004 ¹	10.1	369
710	Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. <i>Journal of Medical Virology</i> , 1994 , 43, 103-10	19.7	292
709	T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. <i>Blood</i> , 2013 , 122, 3138-48	2.2	260
708	Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. <i>Blood</i> , 2000 , 95, 1588-1593	2.2	245
707	T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. <i>Blood</i> , 2003 , 101, 1637-44	2.2	213
706	Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	196
705	S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. <i>Cancer Cell</i> , 2012 , 21, 642-654	24.3	191
704	Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. <i>Blood</i> , 2016 , 127, 2980-90	2.2	191
703	Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. <i>Blood</i> , 2010 , 116, 3129-39; quiz 3377	2.2	175
702	The myth of the second remission of acute leukemia in the adult. <i>Blood</i> , 2013 , 121, 1077-82	2.2	163
701	Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane. <i>Journal of Immunology</i> , 2008 , 180, 7028-38	5.3	160
700	A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 182-7	4.7	151
699	Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 306-15	4.7	143
698	Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). <i>Blood</i> , 2011 , 118, 1413-20	2.2	140

697	Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Breast Cancer Metastasis to the Brain. <i>Clinical Cancer Research</i> , 2018 , 24, 95-105	12.9	139
696	Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. <i>Blood</i> , 2011 , 117, 1888-98	2.2	135
695	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>Haematologica</i> , 2018 , 103, e404-e407	6.6	131
694	Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study. <i>Blood</i> , 2004 , 104, 1898-906	2.2	127
693	TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015 , 21, 3771-82	12.9	117
692	Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. <i>Molecular Therapy</i> , 2015 , 23, 757-68	11.7	116
691	CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 1376-84	6.1	115
690	Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 478-488	12.9	110
689	IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. <i>Cancer Immunology Research</i> , 2019 , 7, 759-772	12.5	109
688	Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6163-71	2.2	107
687	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017 , 35, 24-31	2.2	105
686	Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 858-865	7.1	100
685	Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. <i>Blood</i> , 2005 , 105, 1622-31	2.2	95
684	Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 2136-2140	4.7	94
683	CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. <i>Immunity</i> , 2016 , 44, 913-923	32.3	94
682	Glioma IL13R α 2 is associated with mesenchymal signature gene expression and poor patient prognosis. <i>PLoS ONE</i> , 2013 , 8, e77769	3.7	93
681	US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. <i>Blood Advances</i> , 2016 , 1, 250-259	7.8	91
680	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. <i>Clinical Cancer Research</i> , 2018 , 24, 106-119	12.9	88

679	Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1326-34	4.7	88
678	Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. <i>Blood</i> , 2008 , 112, 903-9	2.2	85
677	A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Cancer Cell</i> , 2016 , 30, 764-778	24.3	84
676	Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 511-7	4.7	82
675	Response: A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 different conditioning regimens. <i>Blood</i> , 2010 , 115, 4317-4317	2.2	78
674	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. <i>Oncotarget</i> , 2018 , 7, e1380764	7.2	74
673	Autologous bone marrow transplantation for non-Hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease. <i>British Journal of Haematology</i> , 1998 , 103, 651-2	4.5	72
672	PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with Zr-Oxine. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1531-1537	8.9	70
671	Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. <i>Nature Medicine</i> , 2018 , 24, 450-462	50.5	69
670	Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	68
669	Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1407-14	4.7	64
668	Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study. <i>JAMA Oncology</i> , 2016 , 2, 1277-1286	13.4	63
667	Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. <i>Blood</i> , 2016 , 128, 1050-8	2.2	61
666	Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies. <i>Blood</i> , 2011 , 117, 309-15	2.2	58
665	Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. <i>Lancet Haematology</i> , 2016 , 3, e87-98	14.6	56
664	Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 3037-48	6.1	55
663	Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia. <i>Blood</i> , 2016 , 127, 1687-700	2.2	55
662	Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 618-624	4.7	54

661	High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. <i>Cancer</i> , 2000 , 89, 680-689	6.4	54
660	Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. <i>Journal of Oncology Practice</i> , 2016 , 12, e1025-e1034	3.1	54
659	Antibodies from donor B cells perpetuate cutaneous chronic graft-versus-host disease in mice. <i>Blood</i> , 2016 , 127, 2249-60	2.2	54
658	Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. <i>Molecular Therapy</i> , 2018 , 26, 280-288	11.7	53
657	Polypeptide-specific antibody response to human cytomegalovirus after infection in bone marrow transplant recipients. <i>Journal of Infectious Diseases</i> , 1986 , 153, 780-7	7	52
656	Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
655	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015 , 100, 357-62	6.6	49
654	Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1864-8	4.7	49
653	TLR9 is critical for glioma stem cell maintenance and targeting. <i>Cancer Research</i> , 2014 , 74, 5218-28	10.1	48
652	Primary anaplastic large-cell lymphoma associated with breast implants. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1481-7	1.9	47
651	Twenty-four-color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2000 , 28, 318-28	5	47
650	Smart CARs engineered for cancer immunotherapy. <i>Current Opinion in Oncology</i> , 2015 , 27, 466-74	4.2	46
649	Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2000 , 1, 46-54		46
648	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 726-733	4.7	45
647	Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 265-269	4.7	44
646	Effective Targeting of TAG72 Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells. <i>Frontiers in Immunology</i> , 2018 , 9, 2268	8.4	44
645	Hemolytic anemia in Wilson disease: clinical findings and biochemical mechanisms. <i>American Journal of Hematology</i> , 1980 , 9, 269-75	7.1	43
644	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. <i>Clinical Cancer Research</i> , 2015 , 21, 2993-3002	12.9	42

643	Cellular immunotherapy and autologous transplantation for hematologic malignancy. <i>Immunological Reviews</i> , 1997 , 157, 231-40	11.3	42
642	Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy 2017 , 5, 26		40
641	Myeloid cell-targeted miR-146a mimic inhibits NF- κ B-driven inflammation and leukemia progression in vivo. <i>Blood</i> , 2020 , 135, 167-180	2.2	40
640	Stabilization of the c-Myc Protein by CAMKII Promotes T Cell Lymphoma. <i>Cancer Cell</i> , 2017 , 32, 115-128.	4.3	38
639	T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2015 , 22, 484-8	3.3	38
638	Cognitive Functioning After Hematopoietic Cell Transplantation for Hematologic Malignancy: Results From a Prospective Longitudinal Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 463-475	2.2	38
637	CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	37
636	Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1900-1903	4.7	37
635	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017 , 179, 781-789	4.5	36
634	Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity. <i>Journal of Immunotherapy</i> , 2007 , 30, 644-54	5	36
633	Extrafollicular CD4 T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. <i>Nature Communications</i> , 2017 , 8, 978	17.4	35
632	Iron chelators induce autophagic cell death in multiple myeloma cells. <i>Leukemia Research</i> , 2014 , 38, 988-96	2.6	35
631	Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia 1996 , 78, 1899-1905		33
630	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2018 , 32, 1567-1574	10.7	31
629	Noncutaneous peripheral T-cell lymphoma histologically resembling mycosis fungoides. <i>Cancer</i> , 1982 , 49, 1839-47	6.4	31
628	Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 691-696	4.7	30
627	Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1463-73	1.9	30
626	Trisomy 11: an association with stem/progenitor cell immunophenotype. <i>British Journal of Haematology</i> , 1995 , 90, 266-73	4.5	30

625	L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. <i>PLoS ONE</i> , 2016 , 11, e0146885	3.7	28
624	Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. <i>Blood</i> , 2021 , 137, 471-484	2.2	28
623	Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. <i>Journal of Clinical Oncology</i> , 2003 , 21, 615-23	2.2	27
622	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 514-520	4.7	27
621	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017 , 176, 759-769	4.5	26
620	Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019 , 187, e45-e48	4.5	26
619	Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. <i>Haematologica</i> , 2018 , 103, 1662-1668	6.6	26
618	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019 , 94, E253-E255	7.1	26
617	Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. <i>Journal of Immunology</i> , 2010 , 184, 4284-94	5.3	26
616	Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020 , 26, 1034-1044	12.9	25
615	Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 575-8	4.7	25
614	High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. <i>Cancer</i> , 1994 , 73, 125-34	6.4	25
613	The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML. <i>Journal of Cellular Physiology</i> , 2019 , 234, 14040-14049	7	25
612	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. <i>Leukemia</i> , 2021 , 35, 189-200	10.7	25
611	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 268-276	4.7	24
610	Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. <i>Cell Stem Cell</i> , 2019 , 25, 542-557.e9	18	23
609	Acute Lymphoblastic Leukemia in the Older Adult. <i>Journal of Oncology Practice</i> , 2019 , 15, 67-75	3.1	23
608	How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. <i>Blood</i> , 2020 , 135, 804-813	2.2	23

607	Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. <i>Blood Advances</i> , 2018 , 2, 1756-1764	7.8	23
606	Pharmacokinetics of high-dose etoposide. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 561-4	6.1	22
605	PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 239-239	2.2	21
604	IFN γ s Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity. <i>Cancer Discovery</i> , 2021 , 11, 2248-2265	24.4	21
603	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. <i>Cancer Discovery</i> , 2021 , 11, 1192-1211	24.4	21
602	Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 75-81	4	20
601	Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 938.e1-938.e6		20
600	Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 700-705	4.7	19
599	Radiation-Related Toxicities Using Organ Sparing Total Marrow Irradiation Transplant Conditioning Regimens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 1025-1033	4	19
598	Acalculous cholecystitis in bone marrow transplant patients. <i>Cancer</i> , 1993 , 71, 354-8	6.4	19
597	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e322-e327	4.7	19
596	Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia. <i>Leukemia Research</i> , 2017 , 59, 124-135	2.7	18
595	Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1326-9	4.7	18
594	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1861-1869	4.7	18
593	Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. <i>Current Opinion in Oncology</i> , 2012 , 24, 182-90	4.2	18
592	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of mutational status. <i>Haematologica</i> , 2017 , 102, 2030-2038	6.6	17
591	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors. <i>Molecular Therapy</i> , 2018 , 26, 695-707	11.7	17
590	Are Disagreements in Caregiver and Patient Assessment of Patient Health Associated with Increased Caregiver Burden in Caregivers of Older Adults with Cancer?. <i>Oncologist</i> , 2017 , 22, 1383-1391	5.7	17

589	CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. <i>Cancer Research</i> , 2017 , 77, 5118-5128	10.1	17
588	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. <i>Journal of the American Geriatrics Society</i> , 2019 , 67, 978-986	5.6	16
587	Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. <i>JAMA Oncology</i> , 2018 , 4, e182453	13.4	15
586	Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2160-2166	4.7	15
585	Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. <i>JAMA Oncology</i> , 2020 , 6, 1947-1951	13.4	15
584	Comparison of naïve and central memory derived CD8 effector cell engraftment fitness and function following adoptive transfer. <i>Onc Immunology</i> , 2016 , 5, e1072671	7.2	14
583	Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 2072-5	4.7	14
582	Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 759-759	2.2	14
581	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3328-3339	2.2	14
580	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia 2016 , 4, 90		14
579	Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. <i>Molecular Therapy</i> , 2021 , 29, 2335-2349	11.7	14
578	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 1193	7.1	13
577	Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis. <i>Cytotherapy</i> , 2017 , 19, 861-866	4.8	12
576	Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation. <i>Supportive Care in Cancer</i> , 2015 , 23, 3141-7	3.9	12
575	Uses and Growth of Hematopoietic Cell Transplantation15-21		12
574	Abnormal growth factor modulation of beta1-integrin-mediated adhesion in chronic myelogenous leukaemia haematopoietic progenitors. <i>British Journal of Haematology</i> , 2001 , 115, 845-53	4.5	12
573	Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort. <i>British Journal of Haematology</i> , 2016 , 174, 480-3	4.5	12
572	Lung Injury Following Hematopoietic Cell Transplantation1456-1472		12

571	The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2020-2023	1.9	11
570	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1084-1090	4.7	11
569	Regulation of miR-34b/c-targeted gene expression program by SUMOylation. <i>Nucleic Acids Research</i> , 2018 , 46, 7108-7123	20.1	11
568	How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation. <i>Blood</i> , 2017 , 130, 1976-1984	2.2	11
567	Cord Blood Hematopoietic Cell Transplantation559-576		11
566	Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.. <i>Blood</i> , 2005 , 106, 1130-1130	2.2	11
565	Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e41-e45	4.7	11
564	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2383-2387	4.7	10
563	What is the role of reduced-intensity transplantation in the treatment of older patients with AML?. <i>Hematology American Society of Hematology Education Program</i> , 2009 , 406-13	3.1	10
562	Integrin β signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells. <i>Oncogene</i> , 2020 , 39, 2156-2169	9.2	10
561	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021 , 9, 75-88	12.5	10
560	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. <i>Blood Advances</i> , 2021 , 5, 4059-4063	7.8	10
559	Manifestations and Treatment of Acute Graft-Versus-Host Disease1287-1303		10
558	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2517-2521	4.7	9
557	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 700-707	4.7	9
556	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1828-1835	4.7	9
555	Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 920-8	4.7	9
554	A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. <i>Blood</i> , 2020 , 136, 18-21	2.2	9

553	Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1212-1217	4.7	9
552	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020 , 55, 473-475	4.4	9
551	Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. <i>Cancer</i> , 2018 , 124, 850-857	6.4	9
550	Uses and Growth of Hematopoietic Cell Transplantation9-15		9
549	State-Transition Analysis of Time-Sequential Gene Expression Identifies Critical Points That Predict Development of Acute Myeloid Leukemia. <i>Cancer Research</i> , 2020 , 80, 3157-3169	10.1	8
548	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 87	22.4	8
547	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. <i>Leukemia</i> , 2019 , 33, 266-270	10.7	8
546	Multi-Center US Intergroup Study of Intensive Chemotherapy Plus Dasatinib Followed By Allogeneic Stem Cell Transplant in Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Younger Than 60. <i>Blood</i> , 2015 , 126, 796-796	2.2	8
545	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2020 , 61, 309-317	1.9	8
544	Chronic Graft-versus-Host Disease: Clinical Manifestations and Therapy1304-1324		8
543	Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 922-929	4.7	7
542	In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function. <i>Journal of Visualized Experiments</i> , 2019 ,	1.6	7
541	Philadelphia chromosome as a recurrent event among therapy-related acute leukemia. <i>American Journal of Hematology</i> , 2017 , 92, E18-E19	7.1	7
540	Acute myeloid leukemia therapeutics: CARs in the driver's seat. <i>Oncolmmunology</i> , 2013 , 2, e27214	7.2	7
539	Adult Patients with ALL Treated with CD62L+ T Naïve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile. <i>Blood</i> , 2018 , 132, 4016-4016	2.2	7
538	Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 19-20	2.2	7
537	Updated Results of High-Dose Yttrium 90 (90Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AH SCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007 , 110, 1891-1891	2.2	7
536	The Pathophysiology of Graft-Vs.-Host Disease353-368		7

535	Oral Complications of Hematopoietic Cell Transplantation1589-1607		7
534	Antitumor efficacy of BAFF-R targeting CAR T cells manufactured under clinic-ready conditions. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2139-2145	7.4	6
533	Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. <i>Blood</i> , 2018 , 131, 2720-2729	2.2	6
532	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019 , 25, 5143-5155	12.9	6
531	Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. <i>Leukemia Research</i> , 2019 , 87, 106230	2.7	6
530	Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2017 ,	10.7	6
529	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. <i>Blood</i> , 2019 , 134, 4075-4075	2.2	6
528	Expression of DLK/PREF1 Results in Inhibition of Human Myeloid Cell Differentiation and Proliferation through Distinct Molecular Mechanisms.. <i>Blood</i> , 2004 , 104, 202-202	2.2	6
527	A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin [®]) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.. <i>Blood</i> , 2006 , 108, 3043-3043	2.2	6
526	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2013 , 122, 2682-2682	2.2	6
525	Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 1153-1161	9.7	6
524	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 877-883	4.4	6
523	Mechanisms and Treatment of Graft Failure 2016 , 944-958		6
522	Growth and Development after Hematopoietic Cell Transplantation1608-1619		6
521	Herpes Simplex Virus Infections1382-1387		6
520	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020 , 11, 962-972	10.3	5
519	Clinical and Genetic Risk Prediction of Cognitive Impairment After Blood or Marrow Transplantation for Hematologic Malignancy. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1312-1321	2.2	5
518	Bone marrow transplantation for hematologic malignancies. <i>Journal of Cellular Physiology</i> , 1982 , 1, 99-102		5

517	Phase 1 Study of MDR1 Inhibitor Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 1636-1636	2.2	5
516	CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL. <i>Blood</i> , 2018 , 132, 610-610	2.2	5
515	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma. A California Cancer Consortium Study.. <i>Blood</i> , 2008 , 112, 1564-1564	2.2	5
514	Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2011 , 118, 664-664	2.2	5
513	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. <i>Blood</i> , 2015 , 126, 519-519	2.2	5
512	Inhibition of MDR1 Overcomes Brentuximab Vedotin Resistance in Hodgkin Lymphoma Cell Line Model and Is Synergistic with Brentuximab Vedotin in Mouse Xenograft Model. <i>Blood</i> , 2016 , 128, 752-752	2.2	5
511	Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma. <i>Blood</i> , 2017 , 130, 738-738	2.2	5
510	Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy. <i>Blood Advances</i> , 2020 , 4, 4798-4801	7.8	5
509	Cord Blood Hematopoietic Cell Transplantation 2016 , 437-455		5
508	Manifestations and Treatment of Acute Graft-versus-Host Disease 2016 , 1012-1025		5
507	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 292-299	4.7	5
506	Hematopoietic Cell Transplantation for Fanconi Anemia 1483-1504		5
505	Pharmacologic Prevention of Acute Graft-Versus-Host Disease 1257-1274		5
504	Fungal Infections after Hematopoietic Cell Transplantation 1346-1366		5
503	Cytomegalovirus Infection 1367-1381		5
502	Varicella-zoster Virus Infections 1388-1409		5
501	Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e183-e185	4.7	4
500	Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1669-1677	1.9	4

499	Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016 , 16, 519-522	2	4
498	The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies. <i>Leukemia Research</i> , 2019 , 84, 106196	2.7	4
497	A History of Allogeneic Hematopoietic Cell Transplantation1-7		4
496	The History of Autologous Hematopoietic Cell Transplantation8-14		4
495	Microcytosis in Hodgkin disease associated with unbalanced globin chain synthesis. <i>American Journal of Hematology</i> , 1986 , 23, 123-9	7.1	4
494	Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas. <i>Blood</i> , 2019 , 134, 4023-4023	2.2	4
493	Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning. <i>Blood</i> , 2019 , 134, 669-669	2.2	4
492	Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL): Outcomes over a 10-Year Period at City of Hope.. <i>Blood</i> , 2004 , 104, 894-894	2.2	4
491	A Phase I Study of the HDAC Inhibitor LBH589 in Combination with Imatinib for Patients with CML in Cytogenetic Remission with Residual Disease Detectable by Q-PCR.. <i>Blood</i> , 2009 , 114, 2194-2194	2.2	4
490	Neurocognitive Function and Its Impact On Return to Work in Patients Treated with Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2009 , 114, 521-521	2.2	4
489	Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL. <i>Blood</i> , 2012 , 120, 3699-3699		4
488	Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed by Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2017 , 130, 518-518	2.2	4
487	Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 861-861	2.2	4
486	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor Redirected-T Cells Against Multiple Myeloma. <i>Blood</i> , 2016 , 128, 812-812	2.2	4
485	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351). <i>American Journal of Hematology</i> , 2021 , 96, E196-E200	7.1	4
484	The Pathophysiology of Graft-versus-Host Disease 2016 , 146-155		4
483	Gastrointestinal and Hepatic Complications 2016 , 1140-1160		4
482	Cytomegalovirus Infection701-726		4

481	Immunological Reconstitution Following Hematopoietic Cell Transplantation853-861		4
480	Growth and Development After Hematopoietic Cell Transplantation929-943		4
479	Pharmacologic Basis for High-dose Chemotherapy287-315		4
478	Bone Marrow and Peripheral Blood Cell Donors and Donor Registries544-558		4
477	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies1043-1051		4
476	Gastrointestinal and Hepatic Complications1434-1455		4
475	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1934-1941	1.9	3
474	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e400-e405	2	3
473	Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. <i>British Journal of Haematology</i> , 2019 , 186, 367-370	4.5	3
472	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1697-1703	4.7	3
471	Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch. <i>Transplantation</i> , 2020 , 104, 1070-1080	1.8	3
470	Immune Reconstitution Following Hematopoietic Cell Transplantation 2016 , 160-169		3
469	Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when?. <i>Best Practice and Research in Clinical Haematology</i> , 2009 , 22, 557-66	4.2	3
468	Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. <i>Hematology/Oncology Clinics of North America</i> , 2009 , 23, 1011-31, vi	3.1	3
467	Graft-vs.-Host Disease633-664		3
466	Genomic Determinants of Response to Blinatumomab in Relapsed/Refractory (R/R) B-Cell Precursor Acute Lymphoblastic Leukemia in Adults. <i>Blood</i> , 2018 , 132, 1552-1552	2.2	3
465	Pre-Clinical Development of a Subunit Vaccine Expressing an IE1-IE2 Fusion Protein of HCMV.. <i>Blood</i> , 2007 , 110, 165-165	2.2	3
464	Persistence of Leukemia Stem Cells in Chronic Myelogenous Leukemia Patients in Complete Cytogenetic Remission on Imatinib Treatment for 5 Years. <i>Blood</i> , 2008 , 112, 194-194	2.2	3

463	First in Human Engraftment of Anti-HIV Lentiviral Vector Gene Modified CD34+ Peripheral Blood Progenitor Cells in the Treatment of AIDS Related Lymphoma (ARL).. <i>Blood</i> , 2008 , 112, 2348-2348	2.2	3
462	Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT. <i>Blood</i> , 2013 , 122, 3374-3374	2.2	3
461	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 522-522	2.2	3
460	Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2015 , 126, 739-739	2.2	3
459	Comparison of Total Body Irradiation-Based with Intravenous Busulfan-Based Chemotherapy-Only Conditioning Regimens for Myeloablative Hematopoietic Cell Transplantation (HCT) in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016 , 128, 679-679	2.2	3
458	Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021 , 138, 133-133	2.2	3
457	A Retrospective Study of Patients Treated with Imatinib Mesylate Prior to Allogeneic Hematopoietic Stem Cell Transplant.. <i>Blood</i> , 2004 , 104, 2752-2752	2.2	3
456	Effect of Growth Factor Stimulation on Imatinib-Mediated Proliferation Inhibition and Apoptosis of CML CD34+ Cells.. <i>Blood</i> , 2004 , 104, 2967-2967	2.2	3
455	Identification of a CD133-CD55- population functions as a fetal common skeletal progenitor. <i>Scientific Reports</i> , 2016 , 6, 38632	4.9	3
454	Uses and Growth of Hematopoietic Cell Transplantation 2016 , 8-17		3
453	Pathology of Hematopoietic Cell Transplantation 2016 , 292-332		3
452	Pharmacologic Prevention of Acute Graft-versus-Host Disease 2016 , 990-1006		3
451	Human Adenovirus, Polyomavirus, and Parvovirus Infections in Patients Undergoing Hematopoietic Stem Cell Transplantation 2016 , 1129-1143		3
450	Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 409-418	4.4	3
449	Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 1662-1664	4.4	3
448	Treatment of allosensitized patients receiving allogeneic transplantation. <i>Blood Advances</i> , 2021 , 5, 4031-4043	4.4	3
447	Hematopoietic Cell Transplantation for Immunodeficiency Diseases1430-1442		3
446	T-Cell Depletion to Prevent Graft-vs.-Host Disease221-233		3

445	Cord Blood Hematopoietic Cell Transplantation550-564		3
444	Gastrointestinal and Hepatic Complications769-810		3
443	Delayed Nonmalignant Complications after Hematopoietic Cell Transplantation1620-1637		3
442	Murine Models of Graft-versus-Host Disease and Graft-versus-Tumor Effect176-187		3
441	Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Cellular Therapy590-604		3
440	Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia761-774		3
439	Hematopoietic Cell Transplantation for Storage Diseases1136-1162		3
438	Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. <i>Cancer</i> , 2020 , 126, 3322-3329	6.4	2
437	Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, e667-e672	2	2
436	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1425-1432	4.7	2
435	Self-endorsed cognitive problems versus objectively assessed cognitive impairment in blood or bone marrow transplantation recipients: A longitudinal study. <i>Cancer</i> , 2020 , 126, 2174-2182	6.4	2
434	Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2261-2266	4.7	2
433	The Pathophysiology of Graft-Versus-Host Disease208-221		2
432	Innovations in autologous transplantation for hematologic malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 28-33	4.7	2
431	CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia.. <i>Leukemia</i> , 2022 ,	10.7	2
430	Nonmyeloablative Therapy and Hematopoietic Cell Transplantation for Hematologic Disorders1164-1176		2
429	Haploidentical mixed chimerism cures autoimmunity in established type 1 diabetic mice. <i>Journal of Clinical Investigation</i> , 2020 , 130, 6457-6476	15.9	2
428	Self-Endorsed Cognitive Problems Vs. Objectively-Assessed Cognitive Impairment in Blood or Marrow Transplantation (BMT) Recipients In Longitudinal Study. <i>Blood</i> , 2018 , 132, 619-619	2.2	2

427	Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 2177-2177	2.2	2
426	The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma. <i>Blood</i> , 2018 , 132, 965-965	2.2	2
425	Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial. <i>Blood</i> , 2020 , 136, 49-50	2.2	2
424	Burden of Long-Term Morbidity after Hematopoietic Cell Transplantation: A Report from the Bone Marrow Transplant Survivor Study (BMTSS).. <i>Blood</i> , 2007 , 110, 832-832	2.2	2
423	HIV Status Does Not Affect the Outcome of Autologous Stem Cell Transplantation (ASCT) for B Cell Non Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2008 , 112, 2181-2181	2.2	2
422	Matched Cohort Analysis of Allogeneic Hematopoietic Cell Transplantation (HCT) with Total Marrow Irradiation/Fludarabine/Melphalan (TFM) Versus Fludarabine/Melphalan (FM) Conditioning for Acute Leukemia. <i>Blood</i> , 2012 , 120, 222-222	2.2	2
421	Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333. <i>Blood</i> , 2014 , 124, 2399-2399	2.2	2
420	Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells. <i>Blood</i> , 2015 , 126, 51-51	2.2	2
419	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015 , 126, 930-930	2.2	2
418	Hematopoietic Cell Transplantation for Storage Diseases 1455-1470		2
417	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical HCT with Post-Transplant Cyclophosphamide: CRS post haploidentical HCT with PTCy. <i>Transplantation and Cellular Therapy</i> , 2021 ,		2
416	Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
415	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2021 ,	6.4	2
414	Developing and Monitoring a Standard-of-Care Chimeric Antigen Receptor (CAR) T Cell Clinical Quality and Regulatory Program. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1386-1393	4.7	2
413	Chlorotoxin Redirects Chimeric Antigen Receptor T Cells for Specific and Effective Targeting of Glioblastoma		2
412	Total marrow irradiation (TMI) with helical tomotherapy and peripheral blood progenitor cell rescue (PBPC) following high-dose melphalan (Mel) and PBPC as part of tandem autologous transplant (TAT) for patients with multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8581-8581	2.2	2
411	The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia 2020 , 8,		2
410	Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2872-2882	2.2	2

409	Efficacy of blinatumomab for MRD relapse in ALL post allogeneic HCT. <i>Leukemia Research</i> , 2021 , 104, 1065-79	2
408	Hematopoietic Stem Cells, Regenerative Medicine, and Leukemogenesis 2016 , 25-57	2
407	Cytomegalovirus Infection 2016 , 1069-1079	2
406	Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 287-292	4-7 2
405	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 486-493	4-7 2
404	Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia 1996 , 78, 1899	2
403	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation	234-24
402	Mechanisms of Tolerance	300-323 2
401	Delayed Complications After Hematopoietic Cell Transplantation	944-961 2
400	Secondary Malignancies After Hematopoietic Cell Transplantation	962-977 2
399	Nutrition Support of the Hematopoietic Cell Transplant Recipient	1551-1569 2
398	Neurologic Complications of Hematopoietic Cell Transplantation	1653-1663 2
397	Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients	1664-1670 2
396	High-dose Preparatory Regimens	316-332 2
395	The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation	443-460 2
394	Psychosocial Issues in Hematopoietic Cell Transplantation	488-501 2
393	Hematopoietic Cell Transplantation from Unrelated Donors	675-691 2
392	Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation	1226-1243 2

391	Kidney and Bladder Complications of Hematopoietic Cell Transplantation	1473-1486		2
390	3D-organoid culture supports differentiation of human CAR iPSCs into highly functional CAR T cells.. <i>Cell Stem Cell</i> , 2022 ,		18	2
389	Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , <i>23</i> , 1264-1268		4.7	1
388	Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. <i>Leukemia</i> , 2018 , <i>32</i> , 2706-2709		10.7	1
387	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. <i>Cancer</i> , 2019 , <i>125</i> , 4033-4042		6.4	1
386	Immune Reconstitution Following Hematopoietic Cell Transplantation	222-231		1
385	Biology of Hematopoietic Stem and Progenitor Cells	36-63		1
384	Biology of Hematopoietic Stem and Progenitor Cells	69-95		1
383	Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination with Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated with Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020 , <i>136</i> , 41-42		2.2	1
382	Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity.. <i>Blood Advances</i> , 2022 ,		7.8	1
381	Large-scale manufacturing and characterization of CMV-CD19CAR T cells. 2022 , <i>10</i> ,			1
380	Outcomes Research in Hematopoietic Cell Transplantation	428-441		1
379	First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results. <i>Blood</i> , 2019 , <i>134</i> , 4394-4394		2.2	1
378	Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. <i>Blood</i> , 2019 , <i>134</i> , 4518-4518		2.2	1
377	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. <i>Blood</i> , 2019 , <i>134</i> , 4525-4525		2.2	1
376	Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). <i>Blood</i> , 2020 , <i>136</i> , 37-38		2.2	1
375	Primary Anaplastic Large Cell Lymphoma of the Breast Occurring in Patients with Silicone Breast Implants.. <i>Blood</i> , 2004 , <i>104</i> , 4563-4563		2.2	1
374	Pregnancy Outcomes after Hematopoietic Cell Transplantation (HCT): A Report from the BMT Survivor Study.. <i>Blood</i> , 2004 , <i>104</i> , 58-58		2.2	1

373	Functional Limitations, Physical Disability and Social Competence among HCT Survivors Transplanted during Childhood or Adolescence: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004 , 104, 59-59	2.2	1
372	Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy with Interleukin-2 Versus Observation for Patients with Non-Hodgkin's Lymphoma: Results of a Phase III Randomized Trial by the Southwest Oncology Group (SwtOG 9438).. <i>Blood</i> , 2006 , 108, 326-326	2.2	1
371	Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.. <i>Blood</i> , 2007 , 110, 4989-4989	2.2	1
370	Total Marrow Irradiation (TMI): A New Ablative Regimen as Part of Tandem (T) Autologous Peripheral Blood Progenitor Cell Transplant (AT) for Patients (pts) with Multiple Myeloma (MM).. <i>Blood</i> , 2008 , 112, 3326-3326	2.2	1
369	Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor. <i>Blood</i> , 2008 , 112, 797-797	2.2	1
368	Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.. <i>Blood</i> , 2009 , 114, 2771-2771	2.2	1
367	Phase I-II Trial of Tandem Autologous Transplantation with Melphalan Followed by Total Marrow Irradiation Ablative Therapy in Patients with Responding or Stable Multiple Myeloma.. <i>Blood</i> , 2012 , 120, 3151-3151	2.2	1
366	Genetic Susceptibility to Anthracycline-Related Congestive Heart Failure (CHF) in Survivors of Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2012 , 120, 589-589	2.2	1
365	Selection For Brentuximab Vedotin Resistant Lymphoma Cell Lines Leads To Downregulation Of Surface CD30 Expression. <i>Blood</i> , 2013 , 122, 1280-1280	2.2	1
364	Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2013 , 122, 4398-4398	2.2	1
363	CS-1 Re-Directed Central Memory T Cell Therapy for Multiple Myeloma. <i>Blood</i> , 2014 , 124, 1114-1114	2.2	1
362	Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies. <i>Blood</i> , 2014 , 124, 4483-4483	2.2	1
361	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 986-986	2.2	1
360	In Utero Transplantation577-589		1
359	Histocompatibility145-162		1
358	Nursing Role in Hematopoietic Cell Transplantation461-477		1
357	Autologous Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma1207-1220		1
356	Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. <i>Blood</i> , 2021 , 138, 2502-2502	2.2	1

355	Donor CD8+ T Cells Facilitate Induction of Chimerism and Tolerance without GVHD in Autoimmune NOD Mice Conditioned with Anti-CD3 mAb.. <i>Blood</i> , 2004 , 104, 1204-1204	2.2	1
354	Matched Unrelated Donor Hematopoietic Cell Transplantation Following Reduced-Intensity Conditioning for Treatment of Myelofibrosis.. <i>Blood</i> , 2004 , 104, 2769-2769	2.2	1
353	Feasibility and Efficacy of Mobilization of BCR/ABL- PBSC in CML Patients Receiving Imatinib.. <i>Blood</i> , 2004 , 104, 2858-2858	2.2	1
352	Health-Related Quality of Life (HRQL) in Adult Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004 , 104, 2254-2254	2.2	1
351	A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in a Week- on Week-Off Dose Schedule in Acute Myelogenous Leukemia.. <i>Blood</i> , 2006 , 108, 1948-1948	2.2	1
350	Outcomes of Patients with T-Lymphoblastic Lymphoma Undergoing Allogeneic Stem Cell Transplantation: Retrospective Results from a Single Center. <i>Blood</i> , 2019 , 134, 5729-5729	2.2	1
349	Effective Combination Immunotherapy using Oncolytic Viruses to Deliver CAR Targets to Solid Tumors		1
348	A Phase I Trial of Total Marrow and Lymphoid Irradiation (TMLI)-Based Transplant Conditioning in Patients (Pts) with Relapsed/Refractory Acute Leukemia. <i>Blood</i> , 2015 , 126, 735-735	2.2	1
347	Yttrium 90 Plus High Dose BEAM Conditioning with Autologous Stem Cell Transplantation (ASCT); Effects of Prior Rituximab and Outcome of Poor Risk Non Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009 , 114, 2323-2323	2.2	1
346	Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3532-3533	1.9	1
345	Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021 , 39, 902-910	2.2	1
344	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 255.e1-255.e9		1
343	Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021 , 106, 851-858	3.8	1
342	Targeted InVivo Delivery of NF-B Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. <i>Molecular Therapy</i> , 2021 , 29, 1214-1225	11.7	1
341	Histocompatibility 2016 , 112-127		1
340	Biology of the Human Graft-versus-Tumor Response and How to Exploit It 2016 , 166-181		1
339	Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Pluripotent Stem Cells 2016 , 16-26		1
338	Hematopoietic Cell Therapy for Human Immunodeficiency Virus Infection 2016 , 781-793		1

337	Oral Complications of Hematopoietic Cell Transplantation 2016 , 1242-1258	1
336	Subsequent Malignant Neoplasms After Hematopoietic Cell Transplantation 2016 , 1275-1289	1
335	Neurologic Complications of Hematopoietic Cell Transplantation 2016 , 1287-1298	1
334	Mechanisms of Tolerance 2016 , 136-149	1
333	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases 2016 , 191-214	1
332	Documentation of Engraftment and Characterization of Chimerism After Hematopoietic Cell Transplantation 2016 , 272-282	1
331	Nursing Role in Hematopoietic Cell Transplantation 2016 , 362-374	1
330	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients 2016 , 392-401	1
329	Hematopoietic Cell Procurement, Processing, and Transplantation 2016 , 414-424	1
328	Bone Marrow and Peripheral Blood Cell Donors and Donor Registries 2016 , 423-432	1
327	Mobilization of Peripheral Blood Hematopoietic Cells for Autologous HCT 2016 , 452-462	1
326	Peripheral Blood Hematopoietic Cells for Allogeneic Transplantation 2016 , 460-471	1
325	Hematopoietic Cell Transplantation for Aplastic Anemia 2016 , 517-540	1
324	Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis 2016 , 724-741	1
323	Hematopoietic Cell Transplantation for Thalassemia 2016 , 842-854	1
322	Hematopoietic Cell Transplantation for Fanconi Anemia 2016 , 923-946	1
321	Blood Group Incompatibilities and Hemolytic Complications of Hematopoietic Cell Transplantation 2016 , 955-962	1
320	Principles of Transfusion Support Before and After Hematopoietic Cell Transplantation 2016 , 961-979	1

319	Chronic Graft-versus-Host Disease [Clinical Manifestations and Therapy 2016 , 1020-1039		1
318	Fungal Infections After Hematopoietic Cell Transplantation 2016 , 1057-1071		1
317	Varicella Zoster Virus Infections 2016 , 1085-1110		1
316	Lung Injury Following Hematopoietic Cell Transplantation 2016 , 1156-1172		1
315	Endocrine Complications Following Hematopoietic Cell Transplantation 2016 , 1181-1207		1
314	Common Potential Drug Interactions Following Hematopoietic Cell Transplantation 2016 , 1206-1217		1
313	Nutrition Support of the Hematopoietic Cell Transplant Recipient 2016 , 1216-1226		1
312	Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. <i>Cancer</i> , 2021 , 127, 794-800	6.4	1
311	Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents. <i>American Journal of Hematology</i> , 2021 , 96, E140-E143	7.1	1
310	Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. <i>Blood Advances</i> , 2021 , 5, 4102-4111	7.8	1
309	Clinical Trials of Gene Marking and Gene Therapy Using Hematopoietic Stem Cells118-129		1
308	Preparative Regimens and Modification of Regimen-Related Toxicities158-177		1
307	Antibody Mediated Purging244-253		1
306	The Experimental Basis for Hematopoietic Cell Transplantation for Autoimmune Diseases324-343		1
305	Murine Models for Graft-Vs.-Host Disease344-352		1
304	Overview of Hematopoietic Cell Transplantation Immunology16-30		1
303	Hematopoietic Cell Donors538-549		1
302	Fungal Infections After Hematopoietic Cell Transplantation683-700		1

301	Herpes Simplex Virus Infections727-731	1
300	Epstein-Barr Virus Infection749-756	1
299	Allogeneic Transplantation for Myelodysplastic and Myeloproliferative Disorders1084-1095	1
298	Hematopoietic Cell Transplantation from Unrelated Donors1132-1149	1
297	Autologous Hematopoietic Cell Transplantation for Multiple Myeloma1262-1282	1
296	Hematopoietic Cell Transplantation for Neuroblastoma1333-1344	1
295	The Human Graft-versus-Tumor Response and How to Exploit It232-247	1
294	Dendritic Cells in Hematopoietic Cell Transplantation248-263	1
293	Documentation of Engraftment and Characterization of Chimerism Following Hematopoietic Cell Transplantation365-37	1
292	Pathology of Hematopoietic Cell Transplantation390-405	1
291	Assessment of Quality of Life in Hematopoietic Cell Transplantation Recipients502-514	1
290	Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors657-674	1
289	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Adults791-805	1
288	Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children806-826	1
287	Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders827-844	1
286	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia897-913	1
285	Hematopoietic Cell Transplantation for Immunodeficiency Diseases1105-1124	1
284	Vascular Access and Complications1244-1256	1

283	Impact of COVID-19 pandemic on global unrelated stem cell donations in 2020-Report from World Marrow Donor Association.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	1
282	Peripheral blood parameter abnormalities precede therapy-related myeloid neoplasms after autologous transplantation for lymphoma.. <i>Cancer</i> , 2021 ,	6.4	1
281	Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine.. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022 , 25, 344-359	6.4	1
280	Oral Complications911-928		1
279	Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma.. <i>Neoplasia</i> , 2022 , 30, 100801	6.4	1
278	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
277	In Vivo Targeting Of Acute Myeloid Leukemia Using CpG-Stat3 siRNA Results In T Cell-Dependent Tumor Eradication. <i>Blood</i> , 2013 , 122, 4212-4212	2.2	0
276	Results from a Phase 1 Study to Evaluate a Memory-Enriched CD19-Specific CAR T Cell Platform in Adult Patients with CD19+ B-Cell Non-Hodgkin Lymphoma (B-NHL). <i>Blood</i> , 2021 , 138, 2836-2836	2.2	0
275	Social Vulnerability Is a Clinically Important Predictor of Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021 , 138, 842-842	2.2	0
274	Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Acute Lymphoblastic Leukemia (B-ALL). <i>Cancer Treatment and Research</i> , 2021 , 181, 179-196	3.5	0
273	The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 2866-2866	2.2	0
272	Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. <i>Blood</i> , 2018 , 132, 3416-3416	2.2	0
271	Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant Recipients: ESPRIT). <i>Blood</i> , 2019 , 134, 4477-4477	2.2	0
270	Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2019 , 134, 707-707	2.2	0
269	Donor derived leukemia in allogeneic transplantation. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2823-2830	1.9	0
268	Delayed Cytomegalovirus (cmv) Infection Following Hematopoietic Cell Transplantation (HCT): City of Hope (COH) Experience.. <i>Blood</i> , 2008 , 112, 1155-1155	2.2	0
267	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2464-2470	4.4	0
266	Pharmacologic Basis for High-dose Chemotherapy 2016 , 211-224		0

265	High-dose Preparatory Regimens 2016 , 223-234		o
264	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021 , 11, 125	7	o
263	Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021 , 114, 544-553	2.3	o
262	Immune Recovery Following Autologous Hematopoietic Stem Cell Transplantation in HIV-Related Lymphoma Patients on the BMT CTN 0803/AMC 071 Trial. <i>Frontiers in Immunology</i> , 2021 , 12, 700045	8.4	o
261	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	o
260	Single-cell analysis by mass cytometry reveals CD19 CAR T cell spatiotemporal plasticity in patients.. <i>Onc Immunology</i> , 2022 , 11, 2040772	7.2	o
259	Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102372	2.2	o
258	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.. <i>British Journal of Haematology</i> , 2021 ,	4.5	o
257	Loss of SIRT1 inhibits hematopoietic stem cell aging and age-dependent mixed phenotype acute leukemia.. <i>Communications Biology</i> , 2022 , 5, 396	6.7	o
256	HIV infection and transplantation 2017 , 290-296		
255	Respiratory Viruses After Hematopoietic Cell Transplantation 2016 , 1112-1125		
254	Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia 2016 , 545-556		
253	Prevention and Treatment of Relapse Following Hematopoietic Cell Transplantation 2014 , 426-431		
252	Radiotherapeutic Principles of Hematopoietic Cell Transplantation 333-350		
251	Expansion of Hematopoietic Stem Cells 88-101		
250	Molecular Biology of Stem Cell Renewal 64-71		
249	Mechanisms of Tolerance 188-207		
248	Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation 102-115		

247 Cellular Biology of Hematopoiesis72-87

246 Hematopoietic Cell Transplantation for Multiple Myeloma845-859

245 Autologous Graft-vs.-Host Disease405-413

244 Should patients with acute lymphoblastic leukemia receive hematopoietic stem-cell transplant from an unrelated donor?. *Nature Clinical Practice Oncology*, **2005**, 2, 18-9

243 Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases. *Blood*, **2020**, 136, 5-6 2.2

242 Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. *Blood*, **2020**, 136, 40-41 2.2

241 Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis. *Blood*, **2020**, 136, 21-22 2.2

240 Severe/Life-Threatening/Fatal Chronic Health Conditions (CHCs) after Allogeneic Blood or Marrow Transplantation (BMT) in Childhood - a Report from the BMT Survivor Study (BMTSS). *Blood*, **2020**, 136, 12-13 2.2

239 Real World Evaluation of Deviation Outcomes in an Immune Effector Cell Quality Program. *Blood*, **2020**, 136, 10-10 2.2

238 Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. *Blood*, **2020**, 136, 10-11 2.2

237 Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors. *Blood*, **2020**, 136, 17-18 2.2

236 Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization. *Blood*, **2020**, 136, 16-17 2.2

235 Pembrolizumab Plus Vorinostat Induces Responses in Patients with Hodgkin Lymphoma Who Are Refractory to Prior PD-1 Blockade. *Blood*, **2021**, 138, 234-234 2.2

234 Dexamethasone Enhanced CAR T Cell Persistence and Function through Upregulation of Interleukin 7 Receptor. *Blood*, **2021**, 138, 1715-1715 2.2

233 Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. *Blood*, **2021**, 138, 3037-3037 2.2

232 Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation - a BMTSS Report. *Blood*, **2021**, 138, 3923-3923 2.2

231 Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation (BMT) Performed over Three Decades - a BMT Survivor Study (BMTSS) Report. *Blood*, **2021**, 138, 484-484^{2.2}

230 CD19/BAFF-R Dual-Targeted CAR T Cells for the Treatment of Mixed Antigen-Negative Variants of Acute Lymphoblastic Leukemia. *Blood*, **2021**, 138, 2783-2783 2.2

229	Developing a Safer Anti-CD44v6 Chimeric Antigen Receptor T Cell Against Hematological Cancers By Mitigating on-Target Off-Tumor Toxicity. <i>Blood</i> , 2021 , 138, 2796-2796	2.2
228	A Randomized Open Label Pilot Study of Clostridium Butyricum Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021 , 138, 334-334	2.2
227	Impact of COVID-19 Pandemic on Global Unrelated Stem Cell Donations in 2020 - Report from World Marrow Donor Association. <i>Blood</i> , 2021 , 138, 3887-3887	2.2
226	Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq. <i>Blood</i> , 2021 , 138, 1808-1808	2.2
225	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021 , 138, 3955-3955	2.2
224	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant. <i>Blood</i> , 2021 , 138, 2887-2887	2.2
223	The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type. <i>Blood</i> , 2021 , 138, 1776-1776	2.2
222	Conditioning Intensity and Probability of Live Birth after Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2021 , 138, 2905-2905	2.2
221	CTIM-29. CLINICAL EVALUATION OF CHLOROTOXIN-DIRECTED CAR T CELLS FOR PATIENTS WITH RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2021 , 23, vi57-vi57	1
220	Single-Cell Analysis By Mass Cytometry Reveals CD19 CAR T Cell Spatiotemporal Plasticity in Patients. <i>Blood</i> , 2021 , 138, 2794-2794	2.2
219	Health Care Utilization by Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004 , 104, 2196-2196	2.2
218	Cytomegalovirus Infections Following Reduced-Intensity Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 2245-2245	2.2
217	Depression, Somatic Distress and Anxiety in Adult Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study.. <i>Blood</i> , 2004 , 104, 231-231	2.2
216	Prognostic Relevance of Early-Onset Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.. <i>Blood</i> , 2004 , 104, 423-423	2.2
215	Predictors of Avascular Necrosis (AVN) of Bone after Long-Term Follow-Up of Allogeneic and Autologous Hematopoietic Cell Transplantation (HCT) for Malignant and Non-Malignant Disorders.. <i>Blood</i> , 2005 , 106, 700-700	2.2
214	Peptide Libraries to CMV Antigens Predict Levels of Cytotoxic Function of CMV-Specific CTL Populations in PBMC from HSCT Recipients.. <i>Blood</i> , 2005 , 106, 478-478	2.2
213	Large Granular Lymphocytosis Following Transplantation: Institutional Experience over a 10-Year Period at City of Hope.. <i>Blood</i> , 2005 , 106, 2024-2024	2.2
212	Pre-Stimulation of CML CD34+ Cells with High Concentrations of Growth Factors Counters Imatinib-Mediated Proliferation Suppression and Enhances Apoptosis of Non-Dividing Cells.. <i>Blood</i> , 2005 , 106, 2479-2479	2.2

- 211 Effects of Elevated BCR/ABL Expression Level on Cellular Transformation and Sensitivity to Imatinib in Primitive Human Hematopoietic Cells.. *Blood*, **2005**, 106, 1998-1998 2.2
- 210 Impact of Chronic Graft Versus Host Disease (cGVHD) on the Health Status of Hematopoietic Cell Transplantation (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. *Blood*, **2005**, 106, 702-702 2.2
- 209 The MDS-Associated Gene DLK Modulates Gene Expression in Human Myeloid Cells by Altering the Activity of Multiple Transcription Factors.. *Blood*, **2005**, 106, 3428-3428 2.2
- 208 Health-Risk Behaviors among Long-Term Hematopoietic Cell Transplant (HCT) Survivors: A Report from the Bone Marrow Transplant Survivor Study.. *Blood*, **2005**, 106, 748-748 2.2
- 207 Combination of the Histone Deacetylase Inhibitor Vorinostat and Dasatinib Increases Apoptosis in Bcr-abl+ Cells and Reverses Changes Associated with CML Progression.. *Blood*, **2006**, 108, 2165-2165 2.2
- 206 Donor CD8+ T Cells Mediate GVL without GVHD in Recipients Conditioned with Anti-CD3 mAb.. *Blood*, **2006**, 108, 192-192 2.2
- 205 Functional Comparison and Longitudinal Assessment of Tri-Functional T-Cells Recognizing CMV pp65 and IE-1 Polypeptides in Hematopoietic Stem Cell and Solid Organ Transplant Recipients.. *Blood*, **2006**, 108, 2936-2936 2.2
- 204 High dose chemotherapy for breast cancer: Out with the old, in with the new?. *Women's Oncology Review*, **2007**, 6, 105-107 2.2
- 203 Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.. *Blood*, **2007**, 110, 3021-3021 2.2
- 202 Non-Myeloablative Conditioning Regimen (NMCR) for Allogeneic Bone Marrow Transplantation (BMT) in Patients with Severe Aplastic Anemia (SAA).. *Blood*, **2007**, 110, 4943-4943 2.2
- 201 Multicytokine and Polyfunctional CMV-Specific T Cells Are Associated with Stem Cell Transplant Donor CMV Serostatus.. *Blood*, **2007**, 110, 4992-4992 2.2
- 200 Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).. *Blood*, **2007**, 110, 1089-1089 2.2
- 199 Antibody-Targeted FISH Analysis Improves Detection of Residual Disease in High Risk B-Cell Acute Lymphoblastic Leukemia.. *Blood*, **2007**, 110, 3500-3500 2.2
- 198 Similar Outcome with Early Reduced Intensity Conditioning (RIC) Allogeneic Transplant to Autologous-Non-Myeloablative Allogeneic (Auto-Allo) Transplant in Patients with Multiple Myeloma.. *Blood*, **2007**, 110, 3030-3030 2.2
- 197 Chronic Graft vs. Host Disease (cGVHD) Hinders Long-Term Functional Recovery after Hematopoietic Cell Transplantation.. *Blood*, **2007**, 110, 634-634 2.2
- 196 In Vivo Activated CD103+CD4+ Regulatory T Cells Ameliorate Ongoing Chronic GVHD.. *Blood*, **2007**, 110, 350-350 2.2
- 195 MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis. *Blood*, **2018**, 132, 1752-1752 2.2
- 194 Novel BAFF-R CAR T-Cell Therapy for CD19 Antigen-Loss Relapsed B Cell Tumors. *Blood*, **2018**, 132, 1411-1411 2.2

193	Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018 , 132, 1549-1549	2.2
192	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018 , 132, 3386-3386	2.2
191	Venous Thromboembolism in Blood or Marrow Transplant (BMT) Survivors: A Report from BMT Survivor Study (BMTSS). <i>Blood</i> , 2018 , 132, 823-823	2.2
190	Targeted Delivery of CpG-Mir-146a Mimic Oligonucleotides As a Therapeutic Strategy to Reduce NF- κ -Mediated Pathogenic Inflammation and Myeloid Leukemia Progression. <i>Blood</i> , 2018 , 132, 3501-3501 ^{2,2}	2.2
189	Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study. <i>Blood</i> , 2018 , 132, 2007-2007	2.2
188	Burden of Morbidity Borne By Survivors of Multiple Myeloma (MM) Treated with Autologous Blood or Marrow Transplant (BMT) [Results of the BMT Survivor Study (BMTSS)]. <i>Blood</i> , 2018 , 132, 2127-2127	2.2
187	DNA Repair Genes May Influence Cognitive Outcomes in Adult Patients with Hematologic Malignancies (HM) Treated with Blood or Marrow Transplantation (BMT). <i>Blood</i> , 2018 , 132, 3411-3411	2.2
186	Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018 , 132, 620-620	2.2
185	Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation. <i>Blood</i> , 2018 , 132, 2181-2181	2.2
184	CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies. <i>Blood</i> , 2018 , 132, 776-776	2.2
183	YIA19-005: Immunotherapy for Prostate Cancer Combining CAR-Engineered T Cells with Targeted Immune Checkpoint Inhibition. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, YIA19-005	7.3
182	Overcoming CD19 Antigen Loss in B-Cell Malignancies with CAR T Cells Targeting BAFF-R. <i>Blood</i> , 2019 , 134, 3871-3871	2.2
181	Longitudinal Trajectory of Frailty in Blood or Marrow Transplant (BMT) Survivors - a BMT Survivor Study (BMTSS). <i>Blood</i> , 2019 , 134, 699-699	2.2
180	Incidence and Risk Factors of De Novo Skin Cancer in a Contemporary Cohort of Hematopoietic Cell Transplantation Survivors. <i>Blood</i> , 2019 , 134, 2011-2011	2.2
179	Randomized Trial of a Novel CMV Vaccine (CMVPepVax) after Allogeneic HCT: Elevated CMV-Specific Immune Response, Reduction in Chronic GvHD and CMV Reactivation Only in Vaccine Arm Patients. <i>Blood</i> , 2014 , 124, 183-183	2.2
178	Feasibility of administering a geriatric assessment to older adults with cancer using web-based and touchscreen platforms.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9536-9536	2.2
177	Differences between patient and caregiver assessments and their association with caregiver burden in caregivers of older adults with cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 9545-9545	2.2
176	Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies. <i>Blood</i> , 2015 , 126, 2731-2731	2.2

- 175 Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation. *Blood*, **2015**, 126, 1961-1961^{2,3}
- 174 Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. *Blood*, **2015**, 126, 3086-3086 2.2
- 173 Radioimmunotherapy-Based Conditioning with Yttrium-90 Ibritumomab Tiuxetan Plus High Dose BEAM for Non-Hodgkin Lymphoma: Does the Regimen Matter?. *Blood*, **2015**, 126, 3179-3179 2.2
- 172 Extrafollicular CD4+ T and B Interaction Induces Chronic Gvhd in the Absence of Germinal Center Formation. *Blood*, **2015**, 126, 1875-1875 2.2
- 171 New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. *Blood*, **2016**, 128, 2161-2161 2.2
- 170 Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. *Blood*, **2016**, 128, 4651-4651 2.2
- 169 Analysis of 120 Pediatric Patients with Non-Malignant Disorders Transplanted Using Unrelated Plasma Depleted Cord Blood and the Role of Post-Thaw Wash. *Blood*, **2008**, 112, 4406-4406 2.2
- 168 Decline in Sexual Functioning Over a 3-Year Period after Hematopoietic Cell Transplantation (HCT): Gender-Specific Impact of Total Body Irradiation (TBI) and Chronic Graft-Versus-Host Disease (cGvHD). *Blood*, **2008**, 112, 743-743 2.2
- 167 Combination Therapy with Histone Deacetylase Inhibitor Vorinostat Plus Aurora Kinase Inhibitor MK-0457 Leads to Enhanced Lymphoma Cell Killing with Stabilization of p53 and Repression of C-Myc, hTERT, and Myc-Responsive miRNAs. *Blood*, **2008**, 112, 3628-3628 2.2
- 166 Longitudinal Trends in Peripheral Blood Parameters Predict Development of Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/ AML) after Autologous Transplantation for Lymphoma.. *Blood*, **2008**, 112, 2133-2133 2.2
- 165 Truncation in CCND1 mRNA 3' UTR Is Associated with An Aggressive Phenotype and Chemoresistance. *Blood*, **2008**, 112, 5287-5287 2.2
- 164 Differential Morbidity by Ethnicity in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). *Blood*, **2008**, 112, 454-454 2.2
- 163 Impact of Donor Serostatus on CMV Reactivation and Reconstitution of Multi-Function CMV-Specific T Cells in CMV-Positive Transplant Recipients. *Blood*, **2008**, 112, 4339-4339 2.2
- 162 Ethnic Differences in the Prevalence of, and Predictors for Anxiety, Depression, and Somatic Distress in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): A Report from the Bone Marrow Transplant Survivor Study (BMTSS). *Blood*, **2008**, 112, 741-741 2.2
- 161 Genomic Alterations in Hodgkin and Reed/Sternberg (HRS) Cells at Disease Onset Reveals Distinct Signatures for Chemosensitive and Primary Refractory Hodgkin Lymphoma.. *Blood*, **2008**, 112, 1451-1451^{2,2}
- 160 Graft Versus Host Disease Correlates with Increased Survival After Allogeneic Stem Cell Transplant for Mature T-Cell Lymphomas: Evidence of Graft Versus T-Cell Lymphoma Effect.. *Blood*, **2009**, 114, 3367-3367^{2,2}
- 159 A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).. *Blood*, **2009**, 114, 1225-1225 2.2
- 158 Late Hospitalizations in Long-Term Survivors of Hematopoietic Cell Transplantation (HCT): Report From the Bone Marrow Transplant Study (BMTSS).. *Blood*, **2009**, 114, 807-807 2.2

157	Y90 Plus High Dose BEAM with Autologous Stem Cell Transplantation for Chemorefractory Non Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 3423-3423	2.2
156	Purity, Potency and Safety: Quality Management Reports (QMR) as the Basis for An Effective Continuous Process Improvement System in An Academic Gene Therapy Program.. <i>Blood</i> , 2009 , 114, 1417-1417	2.2
155	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Can Induce Durable Remission in Heavily Pretreated Relapsed Hodgkin Lymphoma. (HL).. <i>Blood</i> , 2009 , 114, 1192-1192	2.2
154	Mechanisms of Susceptibility to 11q23 MLL Gene Locus Rearrangements in CD34+ Cells Exposed to Etoposide.. <i>Blood</i> , 2009 , 114, 185-185	2.2
153	A Phase II Study of Sequential Velcade/Thalidomide/ Dexamethasone (VTD) as Maintenance Therapy Post Single Autologous Peripheral Stem Cell (PSCT) in Patients with Multiple Myeloma.. <i>Blood</i> , 2009 , 114, 3403-3403	2.2
152	Phase I Study of Bortezomib in Combination with Gemcitabine in Relapsed/Refractory Intermediate Grade B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009 , 114, 1682-1682	2.2
151	Combination Therapy with the Histone Deacetylase Inhibitor Vorinostat Plus the Novel Aurora Kinase A Inhibitor MK-5108 Leads to Enhanced Lymphoma Cell Death Due to Acetylation of p53 and Repression of c-Myc, hTERT, and miRNA Levels.. <i>Blood</i> , 2009 , 114, 1690-1690	2.2
150	Genetic Susceptibility to Therapy-Related Leukemia (t-MDS/AML) After Hodgkin Lymphoma (HL) or Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2009 , 114, 199-199	2.2
149	90.y-Ibritumomab Tiuxetan (Zevalin [®]) May Enhance Anti-Lymphoma Effect of Reduced-Intensity Fludarabine and Melphalan Regimen in Patients with Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Allogeneic Hematopoietic Cell Transplant (Allo-HCT).. <i>Blood</i> , 2009 , 114, 3357-3357	2.2
148	Cause-Specific Conditional Survival In 2603 Consecutive Patients Undergoing Autologous Hematopoietic Cell Transplantation (aHCT) Over a 20-Year Period. <i>Blood</i> , 2010 , 116, 933-933	2.2
147	Dose Dependent Effect of Deferasirox on Hematopoietic Progenitors of Myelodysplastic Syndrome. <i>Blood</i> , 2010 , 116, 3994-3994	2.2
146	Early Mortality After Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies Performed In the Recent Era. <i>Blood</i> , 2010 , 116, 902-902	2.2
145	Extramedullary Relapse Following Reduced Intensity AlloHCT for Adult AML.. <i>Blood</i> , 2010 , 116, 3467-3467	2.2
144	Therapy-Related Myelodysplasia/Acute Myeloid Leukemia (t-MDS/AML) After Conventionally-Treated Breast Cancer: Impact of Cytogenetics on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2011 , 118, 4149-4149	2.2
143	Genetic Susceptibility to Therapy-Related Leukemia [Role of Expression Quantitative Trait Loci (eQTL)]. <i>Blood</i> , 2011 , 118, 2438-2438	2.2
142	Outcome and Prevalence of Hyperdiploidy and Hypodiploidy in Adults with Newly Diagnosed Acute Lymphocytic Leukemia: A SWOG Study. <i>Blood</i> , 2011 , 118, 2555-2555	2.2
141	Nrf2 Deficiency Leads to Altered Hematopoietic Stem Cell Function and Increased Sensitivity to Alkylating Agent Induced Myeloid Dysplasia,. <i>Blood</i> , 2011 , 118, 3828-3828	2.2
140	Tissue Parenchymal Cell Expression of B7-H1 Inhibits Infiltrating T Cell Expansion and Prevents Persistence of Graft-Versus-Host Disease. <i>Blood</i> , 2011 , 118, 2974-2974	2.2

- 139 Costimulatory Molecule Profiles After Autologous Hematopoietic Cell Transplantation (HCT) in Multiple Myeloma (MM) Patients. *Blood*, **2011**, 118, 5108-5108 2.2
- 138 Eosinophilia As a Biomarker Predicting the Occurrence of Chronic Graft Versus Host Disease,. *Blood*, **2011**, 118, 4084-4084 2.2
- 137 Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma. *Blood*, **2011**, 118, 953-953 2.2
- 136 Human Papillomavirus (HPV)-Attributable Subsequent Neoplasms (SNs) After Hematopoietic Cell Transplantation (HCT) Is a Potentially Preventable Outcome. *Blood*, **2012**, 120, 605-605 2.2
- 135 A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. *Blood*, **2012**, 120, 3698-3698 2.2
- 134 Conditional Survival and Cause-Specific Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Hematologic Malignancy Over Three Decades. *Blood*, **2012**, 120, 606-606 2.2
- 133 Dasatinib Enhances Targeting of Human AML Leukemia Stem Cells by Chemotherapeutic Agents Via Activation of p53. *Blood*, **2012**, 120, 3590-3590 2.2
- 132 Nrf2 Deficiency Leads to Reduced Hematopoietic Stem Cell Self-Renewal and Increased Sensitivity to Genotoxic Stressors Through Impaired P53 Function. *Blood*, **2012**, 120, 397-397 2.2
- 131 Phase I Trial of Escalated Doses of Targeted Marrow Radiation Delivered by Tomotherapy Combined with Etoposide and Cyclophosphamide; An Allogeneic HCT Preparative Regimen for Patients with Advanced Leukemia. *Blood*, **2012**, 120, 218-218 2.2
- 130 Quantitative Monitoring Of Wilms Tumor 1 Expression In Predicting Relapse After Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Acute Leukemia and Myelodysplastic Syndrome. *Blood*, **2013**, 122, 2075-2075 2.2
- 129 Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma. *Blood*, **2013**, 122, 1808-1808 2.2
- 128 Increased Risk Of Brain Tumors Among First-Degree Relatives Of Patients With Therapy-Related Myelodysplasia and Acute Myeloid Leukemia (t-MDS/AML). *Blood*, **2013**, 122, 5228-5228 2.2
- 127 Selective Anti Leukemic Activity Of Low Dose Decitabine In Combination With Ruxolitinib Against Stem/Progenitor Cells From Elderly AML Patients. *Blood*, **2013**, 122, 2690-2690 2.2
- 126 Development Of t-MDS In Patients Undergoing Autologous Transplantation For Lymphoma Is Not Associated With Increased Frequency Of Mitochondrial DNA Mutations. *Blood*, **2013**, 122, 1535-1535 2.2
- 125 Long-Term Health-Related Outcomes In Survivors Of Childhood Hematopoietic Cell Transplantation (HCT): A Report From The Bone Marrow Transplant Survivor Study (BMTSS). *Blood*, **2013**, 122, 553-553 2.2
- 124 Cryopreservation of Hematopoietic Cells **2016**, 469-481
- 123 A History of Allogeneic and Autologous Hematopoietic Cell Transplantation **2016**, 1-11
- 122 Marrow Microenvironment and Biology of Mobilization of Stem Cells **2016**, 50-67

121 Expansion of Human Hematopoietic Stem Cells **2016**, 62-70

120 Mesenchymal Stromal Cells and Hematopoietic Cell Transplantation **2016**, 69-79

119 Hematopoietic Cell Transplantation for Immunodeficiency Diseases **2016**, 866-889

118 Genetic Manipulation of Hematopoietic Stem Cells **2016**, 78-99

117 Overview of Hematopoietic Cell Transplantation Immunology **2016**, 96-114

116 Growth and Development After Hematopoietic Cell Transplantation **2016**, 1257-1268

115 Delayed Non-malignant Complications After Hematopoietic Cell Transplantation **2016**, 1266-1276

114 Vaccination of Allogeneic and Autologous Hematopoietic Cell Recipients **2016**, 1297-1306

113 Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation **2016**, 126-138

112 Immune Regulation in Hematopoietic Cell Transplantation **2016**, 153-162

111 Dendritic Cells in Hematopoietic Cell Transplantation **2016**, 178-194

110 Reduced-intensity Allogeneic Transplantation Regimens **2016**, 232-246

109 Radiotherapeutic Principles of Hematopoietic Cell Transplantation **2016**, 244-261

108 Radioimmunotherapy and Hematopoietic Cell Transplantation **2016**, 258-275

107 The Detection and Significance of Minimal Residual Disease **2016**, 281-296

106 Biostatistical Methods in Hematopoietic Cell Transplantation **2016**, 329-341

105 Outcomes Research in Hematopoietic Cell Transplantation **2016**, 341-350

104 The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation **2016**, 349-365

- 103 Ethical Issues in Hematopoietic Cell Transplantation **2016**, 374-385
- 102 Psychosocial Issues in Hematopoietic Cell Transplantation **2016**, 384-393
- 101 Sexuality Following Hematopoietic Cell Transplantation **2016**, 399-408
- 100 Hematopoietic Cell Transplantation **2016**, 407-414
- 99 The Role of the Transplant Program in a Nuclear Accident or Terrorism **2016**, 431-437
- 98 Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation **2016**, 480-491
- 97 Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors **2016**, 489-508
- 96 Hematopoietic Cell Transplantation from Unrelated Donors **2016**, 505-520
- 95 Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria **2016**, 537-546
- 94 Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia **2016**, 554-565
- 93 Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia **2016**, 563-577
- 92 Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia **2016**, 576-590
- 91 Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia in Children **2016**, 600-617
- 90 Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms **2016**, 613-627
- 89 Hematopoietic Cell Transplantation for Multiple Myeloma **2016**, 625-639
- 88 Hematopoietic Cell Transplantation for Hodgkin Disease **2016**, 675-695
- 87 Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma (B Cell) **2016**, 692-705
- 86 Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma (T Cell) **2016**, 703-716

- 85 Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia **2016**, 714-726
- 84 Autologous Hematopoietic Cell Transplantation for Breast Cancer and Germ-cell Tumors **2016**, 739-750
- 83 Hematopoietic Cell Transplantation for Renal Cell Carcinoma and Other Solid Tumors **2016**, 748-761
- 82 Hematopoietic Cell Transplantation for Neuroblastoma **2016**, 760-770
- 81 Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors **2016**, 768-784
- 80 Hematopoietic Cell Transplantation for Autoimmune Diseases **2016**, 792-806
- 79 Adoptive T-cell Therapy for Viral Disease in the Setting of Hematopoietic Cell Transplantation **2016**, 816-827
- 78 Relapse of Hematologic Malignancy After Allogeneic Hematopoietic Transplantation **2016**, 836-844
- 77 Hematopoietic Cell Transplantation for Sickle Cell Disease **2016**, 853-868
- 76 Hematopoietic Cell Transplantation for Storage Diseases **2016**, 885-912
- 75 Hematopoietic Cell Transplantation for Macrophage, Granulocyte and Osteoclast Disorders **2016**, 910-925
- 74 Vascular Access and Complications **2016**, 976-991
- 73 T-cell Depletion to Prevent Graft-versus-Host Disease **2016**, 1004-1014
- 72 Herpes Simplex Virus Infections **2016**, 1078-1086
- 71 EpsteinBarr Virus Infection **2016**, 1105-1113
- 70 HHV-6A, HHV-6B, HHV-7, and HHV-8 After Hematopoietic Cell Transplantation **2016**, 1122-1131
- 69 Kidney and Bladder Complications of Hematopoietic Cell Transplantation **2016**, 1170-1184
- 68 Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation Survivors. *Journal of Investigative Dermatology*, **2021**, 141, 2073-2076.e5 4.3

- 67 A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. *Transplantation and Cellular Therapy*, **2021**, 27, 837.e1-837.e10
- 66 Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. *Leukemia and Lymphoma*, **2021**, 1-7 1.9
- 65 Methods for Gene Transfer: Genetic Manipulation of Hematopoietic Stem Cells 107-117
- 64 AIDS and Hematopoietic Transplantation: HIV Infection, AIDS, Lymphoma and Gene Therapy 1369-1384
- 63 Marrow Transplantation in Thalassemia 1407-1416
- 62 Pharmacologic Basis for High-Dose Chemotherapy 130-157
- 61 Radiotherapeutic Principles of Hematopoietic Cell Transplantation 178-197
- 60 Radioimmunotherapy and Hematopoietic Cell Transplantation 198-208
- 59 Molecular Inhibition of Gene Expression in Hematopoietic Cells 258-271
- 58 The Detection and Significance of Minimal Residual Disease 272-285
- 57 Pathology of Hematopoietic Cell Transplantation 286-299
- 56 Adoptive Immunotherapy With Antigen-Specific T Cells 380-404
- 55 The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation 447-462
- 54 Clinical and Administrative Support for Hematopoietic Cell Transplant Programs 463-468
- 53 Nursing Issues in Hematopoietic Cell Transplantation 469-482
- 52 Psychosocial Issues in Hematopoietic Cell Transplantation 497-506
- 51 Histocompatibility 31-42
- 50 Hematopoietic Cell Procurement, Processing and Transplantation: Regulation and Accreditation 529-537

- 49 In Utero Transplantation 565-575
- 48 Mobilization of Autologous Peripheral Blood Hematopoietic Cells for Support of High-Dose Cancer Therapy 576-587
- 47 Recombinant Growth Factors After Hematopoietic Cell Transplantation 613-623
- 46 The Hematopoietic Microenvironment 53-61
- 45 Nutritional Support of Hematopoietic Cell Recipients 883-893
- 44 Allogeneic Hematopoietic Cell Transplantation for Aplastic Anemia 979-1001
- 43 Allogeneic Hematopoietic Cell Transplantation for Adult Patients With Acute Myeloid Leukemia 1025-1039
- 42 Allogeneic Transplantation for Acute Myeloid Leukemia in Children 1040-1054
- 41 Allogeneic Transplantation for Acute Lymphoblastic Leukemia in Children 1067-1083
- 40 Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma 1096-1104
- 39 Allogeneic Transplantation for Lymphoma and Chronic Lymphocytic Leukemia 1105-1115
- 38 Hematopoietic Cell Transplantation from HLA Partially Matched Related Donors 1116-1131
- 37 Allogeneic Hematopoietic Cell Transplantation for Solid Tumors 1177-1187
- 36 Autologous and Allogeneic Hematopoietic Cell Transplantation for Hodgkin's Disease 1189-1206
- 35 Expansion of Hematopoietic Stem Cells 96-106
- 34 Autologous Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia 1250-1261
- 33 Autologous Hematopoietic Cell Transplantation for AL Amyloidosis 1283-1297
- 32 Hematopoietic Cell Transplantation in Germ Cell Tumors 1308-1319

- 31 Hematopoietic Cell Transplantation for Brain Tumors1345-1353
- 30 Hematopoietic Cell Transplantation for Pediatric Patients With Solid Tumors1354-1368
- 29 Genetic Manipulation of Hematopoietic Stem Cells116-128
- 28 Critical Care of the Hematopoietic Cell Transplant Recipient1539-1550
- 27 Secondary Malignancies after Hematopoietic Cell Transplantation1638-1652
- 26 Natural Killer Cells and Allogeneic Hematopoietic Cell Transplantation163-175
- 25 Radioimmunotherapy and Hematopoietic Cell Transplantation351-364
- 24 The Detection and Significance of Minimal Residual Disease376-389
- 23 Biostatistical Methods in Hematopoietic Cell Transplantation406-427
- 22 Hematopoietic Cell Procurement, Processing, and Transplantation: Standards, Accreditation, and Regulation533-543
- 21 Generation of Definitive Engraftable Hematopoietic Stem Cells from Human Embryonic Stem Cells23-35
- 20 Use of Recombinant Growth Factors after Hematopoietic Cell Transplantation645-656
- 19 Hematopoietic Cell Transplantation for Aplastic Anemia705-726
- 18 Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia751-760
- 17 Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia775-790
- 16 Hematopoietic Cell Transplantation for Hodgkin's Disease860-877
- 15 Non-Hodgkin's Lymphoma878-896
- 14 Autologous Hematopoietic Cell Transplantation for Systemic Light Chain (AL-) Amyloidosis914-930

- 13 Hematopoietic Cell Transplantation for Breast Cancer931-947
- 12 Hematopoietic Cell Transplantation in Germ Cell Tumors948-957
- 11 Hematopoietic Cell Transplantation for Renal Cell and other Solid Tumors958-959
- 10 Hematopoietic Cell Transplantation for Neuroblastoma970-984
- 9 Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors985-1000
- 8 Hematopoietic Cell Transplantation for Patients with Human Immunodeficiency Virus Infection1001-1013
- 7 Hematopoietic Cell Transplantation for Rare Hematologic Malignancies1030-1042
- 6 Management of Relapse after Hematopoietic Cell Transplantation1059-1075
- 5 Hematopoietic Cell Transplantation for Thalassemia1077-1089
- 4 Hematopoietic Cell Transplantation for Fanconi's Anemia1178-1199
- 3 Mechanisms and Treatment of Graft Failure1201-1218
- 2 EpsteinBarr Virus Infection1410-1418
- 1 Common Potential Drug Interactions Following Hematopoietic Cell Transplantation1523-1538